Journal
PATHOLOGY RESEARCH AND PRACTICE
Volume 248, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.prp.2023.154614
Keywords
Pancreatic ductal adenocarcinoma (PDAC); ScRNA-seq; LncRNA; MiRNA; Endothelial cell
Categories
Ask authors/readers for more resources
Using a systems biology approach, we analyzed single cell RNA-seq data to identify differentially expressed genes in PDAC samples compared to adjacent non-cancerous samples. We discovered 1462 DEmRNAs and 27 DElncRNAs, along with dysregulated signaling pathways, abnormally expressed genes, and aberrant cellular functions. These findings have implications for the development of biomarkers and therapeutic targets in PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is a cancer that is usually diagnosed at late stages. This highly aggressive tumor is resistant to most therapeutic approaches, necessitating identification of differentially expressed genes to design new therapies. Herein, we have analyzed single cell RNA-seq data with a systems biology approach to identify important differentially expressed genes in PDAC samples compared to adjacent non-cancerous samples. Our approach revealed 1462 DEmRNAs, including 1389 downregulated DEmRNAs (like PRSS1 and CLPS) and 73 upregulated DEmRNAs (like HSPA1A and SOCS3), 27 DElncRNAs, including 26 downregulated DElncRNAs (like LINC00472 and SNHG7) and 1 upregulated DElncRNA (SNHG5). We also listed a number of dysregulated signaling pathways, abnormally expressed genes and aberrant cellular functions in PDAC which can be used as possible biomarkers and therapeutic targets in this type of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available